Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sets New 1-Year High on Analyst Upgrade

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) hit a new 52-week high on Thursday after Deutsche Bank Aktiengesellschaft upgraded the stock from a hold rating to a buy rating. The stock traded as high as $15.09 and last traded at $15.09, with a volume of 181965 shares changing hands. The stock had previously closed at $13.85.

BAYRY has been the topic of several other research reports. Zacks Research upgraded Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th. DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. UBS Group upgraded Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. Finally, Jefferies Financial Group raised Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Price Performance

The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $59.14 billion, a price-to-earnings ratio of -23.51, a P/E/G ratio of 4.37 and a beta of 0.54. The company’s 50 day moving average is $11.06 and its 200-day moving average is $11.57.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. The firm had revenue of $15.73 billion for the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft had a positive return on equity of 17.61% and a negative net margin of 4.75%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Equities research analysts anticipate that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.